Literature DB >> 23775442

Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device.

Sachiko Hirobe1, Hiroaki Azukizawa, Kazuhiko Matsuo, You Zhai, Ying-Shu Quan, Fumio Kamiyama, Hiroshi Suzuki, Ichiro Katayama, Naoki Okada, Shinsaku Nakagawa.   

Abstract

PURPOSE: We previously reported the safety and efficacy in animal experiments of transcutaneous immunization (TCI) using a self-dissolving microneedle patch (MicroHyala; MH) made of hyaluronic acid and collagen. However, this MH was an unsuitable TCI device for the human skin, as collagen is suspected to induce inflammation. In this study, we developed an improved collagen-free MH (new-MH) and conducted clinical study to evaluate the fundamental properties and safety in human.
METHODS: Microneedle dissolution, skin irritation, and antigen-specific antibody production about new-MH were measured in mice and/or rats. On the basis of the results, the clinical study was conducted in healthy volunteers to evaluate local and systemic adverse events caused by new-MH application.
RESULTS: We confirmed that the microneedles of new-MH, as well as those on our old-MH that contained collagen, could easily pierce stratum corneum without severe skin irritation, and that TCI using new-MH efficiently increased antibody titer with comparable to TCI using old-MH. Application of new-MH caused no severe adverse reactions in 20 healthy volunteers enrolled in a clinical study.
CONCLUSIONS: These results verified that new-MH is a safe TCI device in human, and greatly encouraged us to advance PI/PII clinical studies of antigen-loaded new-MH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775442     DOI: 10.1007/s11095-013-1092-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Breaching the skin's barrier to drugs.

Authors:  Brian W Barry
Journal:  Nat Biotechnol       Date:  2004-02       Impact factor: 54.908

Review 2.  Microneedles for transdermal drug delivery.

Authors:  Mark R Prausnitz
Journal:  Adv Drug Deliv Rev       Date:  2004-03-27       Impact factor: 15.470

3.  Dose sparing with intradermal injection of influenza vaccine.

Authors:  Richard T Kenney; Sarah A Frech; Larry R Muenz; Christina P Villar; Gregory M Glenn
Journal:  N Engl J Med       Date:  2004-11-03       Impact factor: 91.245

Review 4.  Cutaneous dendritic cells.

Authors:  Jenny Valladeau; Sem Saeland
Journal:  Semin Immunol       Date:  2005-08       Impact factor: 11.130

Review 5.  Needle-free vaccine delivery.

Authors:  Gideon Kersten; Hoang Hirschberg
Journal:  Expert Opin Drug Deliv       Date:  2007-09       Impact factor: 6.648

6.  Microfabricated microneedles: a novel approach to transdermal drug delivery.

Authors:  S Henry; D V McAllister; M G Allen; M R Prausnitz
Journal:  J Pharm Sci       Date:  1998-08       Impact factor: 3.534

7.  Differences in immune responses to antibiotics in three guinea-pig strains.

Authors:  T Aida; N Ishikawa; K Shinkai
Journal:  J Toxicol Sci       Date:  1997-12       Impact factor: 2.196

8.  Lack of antigen-specific immune responses in anti-IL-7 receptor alpha chain antibody-treated Peyer's patch-null mice following intestinal immunization with microencapsulated antigen.

Authors:  Jun Kunisawa; Ichiro Takahashi; Akiko Okudaira; Takachika Hiroi; Kazufumi Katayama; Teruko Ariyama; Yasuo Tsutsumi; Shinsaku Nakagawa; Hiroshi Kiyono; Tadanori Mayumi
Journal:  Eur J Immunol       Date:  2002-08       Impact factor: 5.532

9.  Dissolving polymer microneedle patches for influenza vaccination.

Authors:  Sean P Sullivan; Dimitrios G Koutsonanos; Maria Del Pilar Martin; Jeong Woo Lee; Vladimir Zarnitsyn; Seong-O Choi; Niren Murthy; Richard W Compans; Ioanna Skountzou; Mark R Prausnitz
Journal:  Nat Med       Date:  2010-07-18       Impact factor: 53.440

10.  Transdermal delivery of insulin using microneedles in vivo.

Authors:  Wijaya Martanto; Shawn P Davis; Nicholas R Holiday; Jenny Wang; Harvinder S Gill; Mark R Prausnitz
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

View more
  19 in total

1.  Transdermal Delivery of Functional Collagen Via Polyvinylpyrrolidone Microneedles.

Authors:  Wenchao Sun; Mohammed Inayathullah; Martin A C Manoukian; Andrey V Malkovskiy; Sathish Manickam; M Peter Marinkovich; Alfred T Lane; Lobat Tayebi; Alexander M Seifalian; Jayakumar Rajadas
Journal:  Ann Biomed Eng       Date:  2015-06-12       Impact factor: 3.934

2.  The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Authors:  Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz
Journal:  Lancet       Date:  2017-06-27       Impact factor: 79.321

3.  Direct microneedle array fabrication off a photomask to deliver collagen through skin.

Authors:  Jaspreet Singh Kochhar; Parthiban Anbalagan; Sandeep Balu Shelar; Jun Kai Neo; Ciprian Iliescu; Lifeng Kang
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

4.  The maximum possible amount of drug in rapidly separating microneedles.

Authors:  Dan Dan Zhu; Xiao Peng Zhang; Chang Bing Shen; Yong Cui; Xin Dong Guo
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

Review 5.  Beyond antigens and adjuvants: formulating future vaccines.

Authors:  Tyson J Moyer; Andrew C Zmolek; Darrell J Irvine
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

6.  Rapidly dissolvable microneedle patches for transdermal delivery of exenatide.

Authors:  Zhuangzhi Zhu; Huafei Luo; Wangding Lu; Hansen Luan; Yubo Wu; Jing Luo; Youjie Wang; Jiaxin Pi; Chee Yen Lim; Hao Wang
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

7.  Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Authors:  Elena V Vassilieva; Haripriya Kalluri; Devin McAllister; Misha T Taherbhai; E Stein Esser; Winston P Pewin; Joanna A Pulit-Penaloza; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

Review 8.  Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.

Authors:  Jasmin Hassan; Charlotte Haigh; Tanvir Ahmed; Md Jasim Uddin; Diganta B Das
Journal:  Pharmaceutics       Date:  2022-05-16       Impact factor: 6.525

Review 9.  The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.

Authors:  Kamran Badizadegan; James L Goodson; Paul A Rota; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2020-03-17       Impact factor: 5.217

10.  Hydrogel-forming microneedles prepared from "super swelling" polymers combined with lyophilised wafers for transdermal drug delivery.

Authors:  Ryan F Donnelly; Maelíosa T C McCrudden; Ahlam Zaid Alkilani; Eneko Larrañeta; Emma McAlister; Aaron J Courtenay; Mary-Carmel Kearney; Thakur Raghu Raj Singh; Helen O McCarthy; Victoria L Kett; Ester Caffarel-Salvador; Sharifa Al-Zahrani; A David Woolfson
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.